Yamamoto, Shun
Nagashima, Kengo
Kawakami, Takeshi
Mitani, Seiichiro
Komoda, Masato
Tsuji, Yasushi
Izawa, Naoki
Kawakami, Kentaro
Yamamoto, Yoshiyuki
Makiyama, Akitaka
Yamazaki, Kentaro
Masuishi, Toshiki
Esaki, Taito
Nakajima, Takako Eguchi
Okuda, Hiroyuki
Moriwaki, Toshikazu
Boku, Narikazu http://orcid.org/0000-0002-1438-707X
Article History
Received: 7 April 2021
Accepted: 19 October 2021
First Online: 29 October 2021
Declarations
:
: This study was approved by all the participating institutional review boards (National Cancer Center:2017–494, Shizuoka Cancer Center: T30–21–30-1-5, Aichi Cancer Center:2018–1-036, National Hospital Organization Kyushu Cancer Center:2018–8, Tonan Hospital:341, St. Marianna University School of Medical Hospital:4005, Keiyukai Sapporo Hospital:H30–4, University of Tsukuba:H30–234, Japan Community Healthcare Organization Kyushu Hospital:568). It was determined to be a retrospective study of de-identified data, and thus was determined to be exempt from requiring written informed consent.
: This manuscript contains no additional individual person’s data.
: NI and MK, KK, YY, TT, HO, TM2 have nothing to declare. SY has received honoraria from Ono Pharmaceuticals. KN has received honoraria from Pfizer R&D Japan G.K. TK has received honoraria from Chugai, Takeda Pharmaceutical, Taiho. SM has received research funding and honoraria from Taiho, honoraria from Takeda Pharmaceutical, Ono Pharmaceuticals. YT has received honoraria from Bayer, Merck Serono, Lilly, Chugai, Taiho, Ono Pharmaceuticals, Takeda Pharmaceutical, Medicon, Sawai Pharmaceutical. AM has received honoraria from Lilly, Chugai, Takeda Pharmaceutical. KY has received research funding and honoraria from Taiho, honoraria from Chugai, Daiichi Sankyo, Yakult Honsha, Takeda Pharmaceutical, Bayer, Merck Serono, Lilly, Sanofi, Ono Pharmaceuticals, MSD, Bristol-Myers Squibb. TM1 has received research funding from Ono Pharmaceuticals, MSD, Daiichi Sankyo, and honoraria from Takeda Pharmaceutical, Chugai, Merck Bio Pharma, Taiho, Bayer, Lilly, Yakult Honsha, Sanofi, Ono Pharmaceuticals. TE has received research funding from MSD, Novartis, Ono Pharmaceuticals, Daiichi Sankyo, Astellas, Astellas Amgen Biopharma, BeiGene, Pierre Fabre Medicament, Ignyta, Array BioPharma, Merck Serono, Dainippon Sumitomo, Taiho, honoraria from Chugai, Lilly. TN has received research funding from Chugai, Takeda Pharmaceutical, Sanofi, Daiichi Sankyo, Lilly, Nippon Kayaku, Ono Pharmaceuticals, MSD, Astellas, Sumitomo Dainippon Pharma, Eisai, Solasia Pharma, honoraria from Mochida Pharmaceutical, Celltrion Healthcare Japan, Taiho, Merck Serono, Chugai, Takeda Pharmaceutical, Sanofi, Daiichi Sankyo, Lilly, Nippon Kayaku, Ono Pharmaceutical, MSD, Sawai Pharmaceutical, Bayer, Bristol-Myers Squibb, Teijin Pharma, Pfizer, Novartis, Yakult Honsha, Nipro Co. NB has received research funding from Taiho, Ono Pharmaceuticals, honoraria from Taiho, Ono Pharmaceuticals and Bristol-Myers Squibb.